Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsSUBLINGUALGeneric

CASSIPA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

Standard Dose
EQ 16MG BASE;EQ 4MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: N/A Marketing status: Discontinued
Summary

Approval overview CASSIPA is listed in Drugs@FDA under application 208042 (NDA).

Review priority: N/A Marketing status: Discontinued Active ingredient BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE Form and strength FILM;SUBLINGUAL - EQ 16MG BASE;EQ 4MG BASE Sponsor TEVA PHARMS USA Submission history Latest submission status date: 2024-03-20 00:00:00.

Structured Monograph

Clinical summary

Approval overview CASSIPA is listed in Drugs@FDA under application 208042 (NDA). Review priority: N/A Marketing status: Discontinued Active ingredient BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE Form and strength FILM;SUBLINGUAL - EQ 16MG BASE;EQ 4MG BASE Sponsor TEVA PHARMS USA Submission history Latest submission status date: 2024-03-20 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: N/A

Interaction Notes

  • No interaction notes stored yet.